Detalhe da pesquisa
1.
Injection technique of the upper face with onabotulinumtoxinA in chronic migraine.
Headache
; 63(7): 849-860, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37366143
2.
Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial.
Headache
; 63(1): 79-88, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36651532
3.
Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
Headache
; 63(3): 322-332, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36602199
4.
Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle.
Headache
; 63(2): 233-242, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36226464
5.
Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial.
Headache
; 63(3): 377-389, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36704988
6.
Adjunctive treatment of chronic migraine using an oral dental device: overview and results of a randomized placebo-controlled crossover study.
BMC Neurol
; 22(1): 72, 2022 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35246048
7.
Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials.
Headache
; 62(2): 198-207, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35076090
8.
Erenumab dosage for migraine prevention: An evidence-based narrative review with recommendations.
Headache
; 62(4): 420-435, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35137404
9.
Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.
Cephalalgia
; 41(9): 979-990, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33874756
10.
Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.
Cephalalgia
; 41(5): 546-560, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33241721
11.
Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
Headache
; 61(3): 422-429, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33749826
12.
Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
Headache
; 61(4): 642-652, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33818780
13.
Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review.
Headache
; 60(7): 1259-1272, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32602955
14.
No "Wearing-Off Effect" Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study.
Headache
; 60(10): 2431-2443, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33009665
15.
Lasmiditan mechanism of action - review of a selective 5-HT1F agonist.
J Headache Pain
; 21(1): 71, 2020 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32522164
16.
Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety.
J Neurol Neurosurg Psychiatry
; 90(3): 353-360, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30630956
17.
FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
Headache
; 59(10): 1700-1713, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31559634
18.
Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.
J Headache Pain
; 20(1): 10, 2019 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30669961
19.
Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
J Headache Pain
; 20(1): 12, 2019 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30709333
20.
Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
J Headache Pain
; 19(1): 13, 2018 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29404713